(NASDAQ: GERN) Geron's forecast annual revenue growth rate of 1,123.05% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Geron's revenue in 2024 is $237,000.On average, 3 Wall Street analysts forecast GERN's revenue for 2024 to be $30,636,657,531, with the lowest GERN revenue forecast at $4,914,533,781, and the highest GERN revenue forecast at $54,253,722,646. On average, 3 Wall Street analysts forecast GERN's revenue for 2025 to be $131,148,702,420, with the lowest GERN revenue forecast at $21,793,227,022, and the highest GERN revenue forecast at $206,710,751,422.
In 2026, GERN is forecast to generate $237,786,986,697 in revenue, with the lowest revenue forecast at $68,601,430,990 and the highest revenue forecast at $348,315,397,491.